The Patient brings new perspective

Share this article:
Wolters Kluwer is launching The Patient, a quarterly journal that will look at reimbursement issues from a patient perspective.

“We're trying to change the world from one that says ‘no' to medical innovation to one that says, ‘Well, what does the patient think?'” says editor John F. P. Bridges, PhD, of Johns Hopkins Bloomberg School of Public Health. Bridges says formularies, governments and others making decisions about drug access need to break out of the cost-effectiveness model as an exclusive means of determining the value of a medication. The title, intended to complement PharmacoEconomics, will launch in the fourth quarter.

Share this article:

Email Newsletters

More in News

Sanofi expands Gaucher disease portfolio

Sanofi expands Gaucher disease portfolio

The oral medication Cerdelga joins Cerezyme in its Fabry disease arsenal. Sanofi expects the drug will be priced "on par" with Cerezyme, which goes for around $300,000 a year in ...

Amicus seeks to upset Fabry market

Amicus seeks to upset Fabry market

Phase-III tests indicate patients may be able to switch from injectable enzyme-replacement therapies, like Fabrazyme, to the firm's oral drug.

Five things for pharma marketers to know: Wednesday, August 20

Five things for pharma marketers to know: Wednesday, ...

Novartis explores the virtual care space, a court has dismissed a lawsuit against IPAB, Doctors Without Borders calls the Ebola outbreak "a complete disaster" and Pfizer becomes the first pharma ...